Skip to content

Discoveries to Change Lives.

The worrying and increasing development of bacterial
resistance has led to the search of alternative substances
to antibiotics. One of them is the application of phage-encoded
lytic proteins, known as enzybiotics, on which our company is focused.

Telum Therapeutics SL is a global drug discovery biotechnology
company specializing in the use of Engineered Phage Lytic
Proteins as new antimicrobial products.

Numerous studies place the bacteriophages and, specially, their lytic enzymes, as one of the most promising alternatives to the traditional
antibiotics. For this reason, Telum Therapeutics is creating a broad bacteria and phage collection from anthropogenic and cave explorations to obtain new bacteriophages and lytic enzymes with potential antibacterial therapeutic purposes.

Telum’s mission in the field of antibiotic drug development is to give hope to patients suffering with drug resistant infections by developing new antimicrobial agents.

APEXp® under Trade secret protection

Advanced Phage Enzybiotics from exploration platform

01
Sample collection
Sample Collection
02
Metagenome sequencing & lytic enzyme identification
Metagenome sequencing and lytic enzyme identification
03
Phage lytic protein modules
Phage lytic protein modules
04
TT Cloning & Jumbling Technology
TT Cloning and Jumbling Technology
05
Protein Engineering
Protein Engineering
06
High throughput screening
Screening under Relevant conditions
07
Secondary Modifications
Secondary Modifications
08
Select Leading Candidates
Select Leading Candidates

APExTM

Advance Phage Enzybiotics from
exploration platform.

01
Sample collection
02
Metagenome sequencing & lytic enzyme identification
03
Phage lytic protein modules
04
TT Cloning & Jumbling Technology
05
Protein Engineering
06
High throughput screening
07
Secondary Modifications
08
Select Leading Candidates

Telum Therapeutics Development Pipeline

Within our pipeline we have specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa

Program / Product
Pathogen
Discovery
Preclinical
Patent

Ongoing

Future

P001/TT206 (GN EPLE)
Enterobacteriaceae, Pseudomonas aeruginosa Acinetobacter baumannii, including cabapenem resistant strains.
Life-threatening bacteremia
PCT/EP2021/056264
PO02/TT052 (GN EPLE)
Acinetobacter baumannii CRA
Serious infections
Patent application underwriting
PO03 (GN&GP EPLE)
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Cystic Fibrosis
PO04 (GN EPLE)
Enterococcus faecium VRE
Nosocomial infections
PO05 (GN EPLE)
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Serious infections and Skin infections
Program
P001/TT206 (GN EPLE)
Pathogen
Enterobacteriaceae, Pseudomonas aeruginosa Acinetobacter baumannii, including cabapenem resistant strains.
Discovery & Preclinical
Life-threatening bacteremia
Patent
PCT/EP2021/056264
Program
PO02/TT052 (GN EPLE)
Pathogen
Acinetobacter baumannii CRA
Discovery & Preclinical
Serious infections
Patent
Patent application underwriting
Program
PO03 (GN&GP EPLE)
Pathogen
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Discovery
Cystic Fibrosis
Patent
Program
PO04 (GN EPLE)
Pathogen
Enterococcus faecium VRE
Discovery
Nosocomial infections
Patent
PCT/EP2021/056564
Program
PO05 (GN EPLE)
Pathogen
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Discovery
Preclinical
Serious infections and Skin infections
Patent

Abbreviations: EPLE: Engineered Phage Lytic Enzyme; GN, Gram negative bacteria; GP, Gram positive bacteria; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp